Oral Oresentation 4

4:00 PM - 4:06 PM JST(7:00 AM - 7:06 AM UTC)

[O04-06] The efficacy and safety of guselkumab versus placebo in Chinese patients with moderately to severely active Crohn's disease: Results of the GALAXI 2 and GALAXI 3 Phase 3 Studies

*Baili Chen¹, Jie Zhang², Qian Cao³, Xiang Gao⁴, Yan Zhang⁵, Hong Chen⁶, Yan Chen⁷, Xuan Guo⁸, Rian Van Rampelbergh⁹, Jiajia Lu¹⁰, Wilbert van Duijnhoven⁹, Minhu Chen¹ (1. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China, 2. The Second Xiangya Hospital, Central South University, Changsha, P.R. China, 3. Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China, 4. The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China, 5. West China Hospital, Sichuan University, Chengdu, P.R. China, 6. Zhongda Hospital, Southeast University, Nanjing, P.R. China, 7. The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China, 8. Johnson & Johnson, Beijing, P.R. China, 9. Janssen Research & Development, LLC, Antwerp, Belgium, 10. Johnson & Johnson, Shanghai, P.R. China)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.